Tagreed Alkaltham: Fibrinogen Concentrate Is a Deliberate Clinical Choice in Acute Bleeding
Tagreed Alkaltham, Transfusion Medicine Lab Supervisor at KSMC, shared a post on LinkedIn:
“Fibrinogen concentrate is not a shortcut.
It’s a deliberate clinical choice.
In acute bleeding, fibrinogen concentrate is often discussed in terms of speed and convenience. But its real value is not how fast it can be given – it’s when and why it is given. It’s when fibrinogen deficiency is addressed, and why supporting clot stability early matters.
Fibrinogen concentrate provides a known, standardized dose, without the volume burden or preparation time associated with cryoprecipitate. In critical bleeding, knowing what to expect makes the decision safer.
It’s not that fibrinogen’s role in coagulation is unknown; the difference lies in how early it is addressed, before bleeding escalates into loss of control.
When used appropriately, it allows teams to:
- correct hypofibrinogenemia promptly
- avoid unnecessary volume overload
- and target the hemostatic deficit more precisely
From a blood bank perspective, fibrinogen concentrate represents a shift in thinking: from reactive transfusion
to intentional hemostatic management.
From a blood bank perspective, fibrinogen concentrate also offers operational clarity. It reduces pressure on cryoprecipitate stock, which is often limited, variable in availability, and time sensitive once thawed. Its longer shelf life allows for better inventory stability, without compromising readiness for true bleeding emergencies.
It requires clear protocols, shared clinical understanding, and respect for timing.
- Used thoughtfully, it strengthens care.
- Used casually, it becomes just another product.
In bleeding patients, precision is not a luxury – it is part of patient safety.Its value lies in judgment, not availability.”
Other posts featuring Tagreed Alkaltham on Hemostasis Today.
-
Jul 13, 2026, 17:39Pascal Boulanger: Send a Postcard to Your Lab Staff From ISTH 2026
-
Jul 13, 2026, 17:21Stefano Navarro: Presenting Our Recently Published Article at ISTH 2026
-
Jul 13, 2026, 17:12Santagata Davide: A Great Session and an Incredible Opportunity to Present Our Research at ISTH 2026
-
Jul 13, 2026, 16:26Real-World Data Across Time Reveal Important Advances in Hemophilia Treatment – ATHN
-
Jul 13, 2026, 16:19Mary Cushman: Celebrating Our Incredible ISTH Council Members in Paris
-
Jul 13, 2026, 16:17Wolfgang Miesbach: Gene Therapy Shows Promising Early Results in Adolescents With Hemophilia B at ISTH 2026
-
Jul 13, 2026, 16:06Dino Mehic: Honored to Receive the ISTH Early Career Top Reviewer Awards
-
Jul 13, 2026, 16:01Advancing DIC Diagnosis in Cirrhosis Through Disease-Specific Risk Stratification – JTH
-
Jul 13, 2026, 15:52Joshua Muia: Presenting Our Research on ADAMTS13/VWF Dysregulation in Sepsis at ISTH 2026